

**DIVI'S LABORATORIES LIMITED**

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2012

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	<b>Income from operations</b>	<b>53333</b>	47260	41658	<b>147434</b>	113153	183949
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	<b>103</b>	114	82	<b>327</b>	197	544
	<b>Total Income from operations (net)</b>	<b>53436</b>	47374	41740	<b>147761</b>	113350	184493
2	<b>Expenses</b>						
	a. Cost of materials consumed	<b>26080</b>	23131	20476	<b>66468</b>	53407	77177
	b. Purchases of stock-in-trade	<b>14</b>	0	0	<b>14</b>	0	10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(3972)</b>	(6978)	(4243)	<b>(12124)</b>	(8337)	(1066)
	d. Employee benefits expense	<b>4552</b>	4337	3590	<b>13734</b>	10123	14516
	e. Depreciation and amortization expense	<b>2036</b>	1879	1620	<b>5663</b>	4540	6203
	f. Other Expenses	<b>8531</b>	10385	6800	<b>23707</b>	17276	24369
	<b>Total Expenses</b>	<b>37241</b>	32754	28243	<b>97462</b>	77009	121209
3	<b>Profit from Operations before Other Income, Finance Costs &amp; Exceptional Items (1-2)</b>	<b>16195</b>	14620	13497	<b>50299</b>	36341	63284
4	Other Income	<b>2232</b>	847	2554	<b>5067</b>	6140	6576
5	<b>Profit from ordinary activities before finance costs &amp; exceptional Items (3+4)</b>	<b>18427</b>	15467	16051	<b>55366</b>	42481	69860
6	Finance Costs	<b>44</b>	31	11	<b>116</b>	132	374
7	<b>Profit from ordinary activities after finance costs but before exceptional Items (5-6)</b>	<b>18383</b>	15436	16040	<b>55250</b>	42349	69486
8	Exceptional items	<b>0</b>	0	0	<b>0</b>	0	0
9	<b>Profit from ordinary activities before Tax (7-8)</b>	<b>18383</b>	15436	16040	<b>55250</b>	42349	69486
10	Tax Expense	<b>3959</b>	3639	3785	<b>12291</b>	9230	14889
11	<b>Net Profit from ordinary activities after Tax (9-10)</b>	<b>14424</b>	11797	12255	<b>42959</b>	33119	54597
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	<b>0</b>	0	0
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>14424</b>	11797	12255	<b>42959</b>	33119	54597
14	Share of profit / (loss) of associates	<b>0</b>	0	0	<b>0</b>	0	0
15	Minority Interest	<b>0</b>	0	0	<b>0</b>	0	0

16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	14424	11797	12255	42959	33119	54597
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2654	2655	2654	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						214825
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	10.86	8.89	9.24	32.36	24.97	41.15
	b) Diluted	10.86	8.89	9.24	32.36	24.97	41.15
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	10.86	8.89	9.24	32.36	24.97	41.15
	b) Diluted	10.86	8.89	9.24	32.36	24.97	41.15

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	63512190 47.85%	63512190 47.85%	63481010 47.84%	63512190 47.85%	63481010 47.84%	63512190 47.85%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil  69222100 100%  52.15%	Nil  69222100 100%  52.15%	Nil  69222100 100%  52.16%	Nil  69222100 100%  52.15%	Nil  69222100 100%  52.16%	Nil  69222100 100%  52.15%

	Particulars	Quarter ended 31-12-2012
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	17
	Disposed off during the quarter	17
	Remaining unresolved at the end of the quarter	Nil

**NOTES:**

- The above results for the period ended 31<sup>st</sup> December 2012, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 2<sup>nd</sup> February, 2013 and were subjected to 'limited review' by the Auditors.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.

3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited Standalone Results and to publish consolidated results at the year end.
4. Accounts have been reclassified as per the revised Schedule VI to Companies Act, 1956. Directors' Remuneration which was included earlier under Other Expenditure has now been included under Employee Cost.
5. Figures for the previous year/periods have also been regrouped or recasted, wherever necessary.

for Divi's Laboratories Limited

Place: Hyderabad

Date: 02-02-2013

Dr. Murali K. Divi  
Chairman & Managing Director